2,6-ジイソプロピルフェノール

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

2,6-ジイソプロピルフェノール 価格

MSDS Information

• Propofol

2,6-ジイソプロピルフェノール 化学特性,用途語,生産方法

• 外観

  無色～黄褐色又は褐色、液体

• 用途

  イソプロピルフェノール誘導 体です。GABAA 受容体に作用し、麻酔作用 を示します。

• 用途

  イソプロピルフェノール誘導 体です。GABAA 受容体に作用し、麻酔作用 を示します。

• 効能

  静脈麻酔薬, GABA-A受容体作動薬

• 商品名

  ディプリバン (アスペンジャパン); ディプリバン (アスペンジャパン)

• 説明

  Propofol is an injectable, short-acting general anesthetic with a low incidence of side effects.

• 化学的特性

  Light Yellow Liquid

• 使用

  Propofol is an anesthetic used in veterinary medicine.

• 世界保健機関（WHO）

  Propofol, a short acting injectable anaesthetic, was introduced in 1987. In April 1992, the Norwegian Medicines Control Board reported that prolonged use of propofol had been associated with two fatalities in children characterized by metabolic acidosis, liver enlargement, and cerebral oedema. The UK Committee on the Safety of Medicines has received 5 reports of deaths occurring in children who had received propofol while in intensive care.

• 生物学の機能

  Propofol (Diprivan) is rapidly acting, has a short recovery time, and possesses antiemetic properties. A rapid onset of anesthesia (50 seconds) is achieved, and if no other drug is administered, recovery will take place in 4 to 8 minutes.The recovery is attributed to redistribution of the drug and rapid metabolism to glucuronide and sulfate conjugates by the liver and extrahepatic tissues, such as intestine and kidney.
  Rapid recovery and its antiemetic properties make propofol anesthesia very popular as an induction agent for outpatient anesthesia. Propofol can also be used to supplement inhalational anesthesia in longer procedures. Both continuous infusion of propofol for conscious sedation and with opioids for the maintenance of anesthesia for cardiac surgery are acceptable techniques.

• 一般的な説明

  Propofol is an injectable sedative–hypnotic used for the inductionand maintenance of anesthesia or sedation. Propofolis only slightly soluble in water with an octanol/water partitioncoefficient of 6,761:1; thus, it is formulated as an oil-inwateremulsion. The fat component of the emulsion consistsof soybean oil, glycerol, and egg lecithin. The pKa of thepropanol hydroxyl is 11 and the injectable emulsion has apH of 7 to 8.5. Formulations contain either disodium ethylenediaminetetraaceticacid (EDTA) (0.005%) or sodiummetabisulfite to retard the growth of microorganisms. EDTAis a metal chelator and patients on propofol containingEDTA for extended periods of time excrete more zinc andiron in their urine. The clinical consequence of this is notknown but the manufacturer recommends that a drug holidayor zinc supplementation be considered after 5 days of therapy.

• 生物活性

  Intravenous general anesthetic and hypnotic with a mode of action which includes potentiation of GABA-mediated inhibitory synaptic transmission, direct activation of the GABA A receptor and inhibition of glutamate receptor mediated excitatory synaptic transmission. Also potentiates P2X 4 receptor-mediated currents in P2X 4 -HEK293 cells.

• 薬理学

  Propofol is primarily a hypnotic drug with substantial cardiorespiratory depressant actions and with no ability to produce neuromuscular blockade. While propofol lacks analgesic properties, its use permits lower doses of opioids. Likewise, less propofol is required for adequate hypnosis when it is administered with opioids.Thus, it is said that propofol and opioids interact synergistically.

• 臨床応用

  Generic formulations of propofol may contain sodiummetabisulfite as the antimicrobial agent, and patients allergicto sulfites, especially asthmatic patients, should avoid thisformulation. Aseptic technique must be followed and unusedportions of the drug must be discarded according to the manufacturer’s instructions to prevent microbial contaminationand possible sepsis.

• 副作用

  The dose of propofol should be reduced in older patients; however, it does have a relatively linear dose– response characteristic, and patients generally can be safely titrated. The pain on injection, especially when small veins are used, can be considerably reduced if lidocaine 20 mg is administered first.
  Anesthesia induction with propofol causes a significant reduction in blood pressure that is proportional to the severity of cardiovascular disease or the volume status of the patient, or both. However, even in healthy patients a significant reduction in systolic and mean arterial blood pressure occurs. The reduction in pressure appears to be associated with vasodilation and myocardial depression. Although propofol decreases systemic vascular resistance, reflex tachycardia is not observed. This is in contrast to the actions of thiopental. The heart rate stabilization produced by propofol relative to other agents is likely the result of either resetting or inhibiting the baroreflex, thus reducing the tachycardic response to hypotension.
  Since propofol does not depress the hemodynamic response to laryngoscopy and intubation, its use may permit wide swings in blood pressure at the time of induction of anesthesia. Propofol should be used with utmost caution in patients with cardiac disease.

• 安全性プロファイル

  Poison by intravenous and intraperitoneal routes. Experimental reproductive effects. Combustible when exposed to heat or flame; can react with oxidizing materials. To fight fire, use foam, CO2, dry chemical. When heated to decomposition it emits acrid smoke and fumes. See also PHENOL

2,6-ジイソプロピルフェノール 上流と下流の製品情報

2,6-ジイソプロピルフェノール 生産企業

Global(442)Suppliers

2,6-ジイソプロピルフェノール スペクトルデータ(¹HNMR、¹³CNMR、IR1、MS、Raman)

2078-54-8, 2,6-ジイソプロピルフェノール キーワード